MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing

§ 01 Executive Snapshot

• What: MindMaze Therapeutics has completed an organizational simplification and provided an update on its equity financing with Neuro.io.
• Who: MindMaze Therapeutics Holding SA and Neuro.io Group SA.
• Why it matters: These initiatives are crucial for MindMaze as they focus on enhancing their operations in the neurology sector and securing necessary funding for future growth.

§ 02 Key Developments

• MindMaze completed its organizational simplification by disposing of nearly all non-neurology legacy operations, aiming to reduce costs and concentrate on its core business.
• The initial tranche of CHF 8.0 million strategic equity financing from Neuro.io has been completed, yielding CHF 4.0 million in gross cash proceeds.
• 4,970,000 treasury shares were transferred to Neuro.io, and CHF 2,850,900 in mandatory convertible loan notes were converted into 12,395,217 ordinary shares.
• The second tranche of CHF 4.0 million is expected to be funded in two installments during September and November 2026.
• MindMaze is seeking additional financing to enhance liquidity, with updates to be provided as developments occur.

§ 03 Strategic Context

• MindMaze's organizational simplification aligns with a broader trend in the healthcare sector where companies streamline operations to focus on core competencies, particularly in specialized fields like neurology.
• The strategic equity financing with Neuro.io illustrates the increasing collaboration between tech companies and healthcare firms to advance innovative therapeutic solutions.

§ 04 Strategic Implications

• The immediate consequence of the organizational simplification is a leaner operation for MindMaze, which may enhance its competitive position in the neurotherapeutics market.
• Long-term, the successful completion of the financing and operational focus may position MindMaze as a leader in neurorestorative medicine, attracting further investment and partnerships.

§ 05 Risks & Constraints

• Potential risks include uncertainties regarding the timing or completion of the second tranche of financing, which could affect liquidity and operational plans.
• The competitive landscape in the neurotherapeutics space remains intense, with other firms potentially vying for similar funding and market share.

§ 06 Watchlist / Forward Signals

• The funding schedule for the second tranche in September and November 2026 will be a critical indicator of MindMaze's financial health and operational progress.
• Future updates on additional financing efforts will signal the company's ability to sustain operations and invest in growth initiatives.